![Elaine Ferguson SFHEA PhD MPharm MRPharmS FAPS](https://profiles-cardiff.imgix.net/attachments/1643?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Elaine Ferguson
(hi/ei)
SFHEA PhD MPharm MRPharmS FAPS
Darllenydd mewn Therapiwteg Polymer a Chyfarwyddwr Ymchwil
- FergusonEL@caerdydd.ac.uk
- +44 29225 10663
- Ysbyty Deintyddol y Brifysgol, Ystafell Room 5F.08, Parc y Mynydd Bychan, Caerdydd, CF14 4XY
- Sylwebydd y cyfryngau
- Ar gael fel goruchwyliwr ôl-raddedig
Trosolwyg
Tissue Engineering & Reparative Dentistry Microbial Effects on Tissue Function, and Tissue Repair and Remodelling Repair and Regeneration in the Oral MucosaResearch Theme
Research Group
Research Interests
Selected Publications
Selected Projects
Cyhoeddiad
2024
- Rizzo, S., Varache, M., Sayers, E. J., Jones, A. T., Tonks, A., Thomas, D. W. and Ferguson, E. L. 2024. Modification of the antibiotic, colistin, with dextrin causes enhanced cytotoxicity and triggers apoptosis in myeloid leukemia. International Journal of Nanomedicine 19, pp. 5419-5437. (10.2147/IJN.S449185)
- Wootton, H. S., Berry, S. S., Ferguson, E. L., Mahon, C. S. and Miller, G. J. 2024. Adaptable synthesis of chondroitin sulfate disaccharide subtypes preprogrammed for regiospecific O-sulfation. Organic Chemistry (10.26434/chemrxiv-2024-nlm1k)
- Varache, M. et al. 2024. Dextrin conjugation to colistin inhibits its toxicity, cellular uptake and acute kidney injury in vivo. RSC Pharmaceutics 1, pp. 68-79. (10.1039/D3PM00014A)
2023
- Sharma, P. et al. 2023. In vitro antibiofilm activity of hexylresorcinol lozenges against oropharyngeal pathogens. Presented at: 2023 ERS International Congress, Milan, Italy, 9-13 September 2023. European Respiratory Society, (10.1183/13993003.congress-2023.PA603)
2022
- Stokniene, J., Varache, M., Rye, P. D., Hill, K. E., Thomas, D. W. and Ferguson, E. L. 2022. Alginate oligosaccharides enhance diffusion and activity of colistin in a mucin-rich environment. Scientific Reports 12, article number: 4986. (10.1038/s41598-022-08927-1)
2021
- Chiron, E., Varache, M., Stokniene, J., Thomas, D. W. and Ferguson, E. L. 2021. A physicochemical assessment of the thermal stability of dextrin–colistin conjugates. Scientific Reports 11, article number: 10600. (10.1038/s41598-021-89946-2)
2020
- Stokniene, J. et al. 2020. Bi-functional alginate oligosaccharide–polymyxin conjugates for improved treatment of multidrug-resistant gram-negative bacterial infections. Pharmaceutics 12(11), article number: 1080. (10.3390/pharmaceutics12111080)
2019
- Ferguson, E., Varache, M., Stokniene, J. and Thomas, D. 2019. Polysaccharides for protein and peptide conjugation. In: Pasut, G. and Zalipsky, S. eds. Polymer-Protein Conjugates: From Pegylation and Beyond. Elsevier, pp. 421-453., (10.1016/B978-0-444-64081-9.00019-X)
- Varache, M., Powell, L. C., Aarstad, O. A., Williams, T. L., Wenzel, M. N., Thomas, D. W. and Ferguson, E. L. 2019. Polymer masked-unmasked protein therapy: Identification of the active species after amylase-activation of dextrin-colistin conjugates.. Molecular Pharmaceutics 16(7), pp. 3199-3207. (10.1021/acs.molpharmaceut.9b00393)
2018
- Ferguson, E. L. et al. 2018. Controlled release of Dextrin-conjugated growth factors to support growth and differentation of neural stem cells. Stem Cell Research 33, pp. 69-78. (10.1016/j.scr.2018.10.008)
- Powell, L. C. et al. 2018. Targeted disruption of the extracellular polymeric network of pseudomonas aeruginosa biofilms by alginate oligosaccharides. npj Biofilms and Microbiomes 4, article number: 13. (10.1038/s41522-018-0056-3)
2017
- Scomparin, A., Florindo, H. F., Tiram, G., Ferguson, E. L. and Satchi-Fainaro, R. 2017. Two-step polymer- and liposome- enzyme prodrug therapies for cancer: PDEPT and PELT concepts and future perspectives. Advanced Drug Delivery Reviews 118, pp. 52-64. (10.1016/j.addr.2017.09.011)
- Ferguson, E. L., Scomparin, A., Hailu, H. and Satchi-Fainaro, R. 2017. HPMA copolymer-phospholipase C and dextrin-phospholipase A2 as model triggers for polymer enzyme liposome therapy (PELT). Journal of drug targeting 25(9-10), pp. 818-828. (10.1080/1061186X.2017.1358726)
- Pritchard, M. F. et al. 2017. The antimicrobial effects of the alginate oligomer OligoG CF-5/20 are independent of direct bacterial cell membrane disruption. Scientific Reports 7, article number: 44731. (10.1038/srep44731)
2016
- Roberts, J. L., Cattoz, B., Schweins, R., Beck, K., Thomas, D. W., Griffiths, P. C. and Ferguson, E. L. 2016. In vitro evaluation of the interaction of dextrin-colistin conjugates with bacterial lipopolysaccharide. Journal of Medicinal Chemistry 59(2), pp. 647-654. (10.1021/acs.jmedchem.5b01521)
2015
- Azzopardi, E. A., Ferguson, E. L. and Thomas, D. W. 2015. Development and validation of an in vitro pharmacokinetic/pharmacodynamic model to test the antibacterial efficacy of antibiotic polymer conjugates. Antimicrobial Agents and Chemotherapy 59(4), pp. 1837-1843. (10.1128/AAC.03708-14)
2014
- Ferguson, E. L., Azzopardi, E., Roberts, J. L., Walsh, T. R. and Thomas, D. W. 2014. Dextrin-Colistin conjugates as a model bioresponsive treatment for multidrug resistant bacterial infections. Molecular Pharmaceutics 11(12), pp. 4437-4447. (10.1021/mp500584u)
- Azzopardi, E. A., Ferguson, E. L. and Thomas, D. W. 2014. A novel class of bioreponsive nanomedicines for localised reinstatement of bioactivity and specific targeting [Abstract]. The Lancet 383, pp. S9. (10.1016/S0140-6736(14)60272-5)
2013
- Azzopardi, E. A., Ferguson, E. L. and Thomas, D. W. 2013. Colistin past and future: A bibliographic analysis. Journal of Critical Care 28(2), pp. 219.e13-219.e19. (10.1016/j.jcrc.2012.04.008)
- Azzopardi, E. A., Ferguson, E. L. and Thomas, D. W. 2013. The enhanced permeability retention effect: a new paradigm for drug targeting in infection. Journal of Antimicrobial Chemotherapy 68(2), pp. 257-274. (10.1093/jac/dks379)
- Naderi, N., Madani, S. Y., Ferguson, E. L., Mosahebi, A. and Seifalian, A. M. 2013. Carbon nanotubes in the diagnosis and treatment of malignant melanoma. Anti-Cancer Agents in Medicinal Chemistry 13(1), pp. 171-185. (10.2174/1871520611307010171)
- Azzopardi, E. A., Camilleri, L., Moseley, R., Thomas, D. W. and Ferguson, E. L. 2013. Statistical characterization of succinoylated dextrin degradation behavior in human α-amylase. Journal of Carbohydrate Chemistry 32(7), pp. 438-449. (10.1080/07328303.2013.831434)
2011
- Ferguson, E. L., Roberts, J. L., Moseley, R., Griffiths, P. C. and Thomas, D. W. 2011. Evaluation of the physical and biological properties of hyaluronan and hyaluronan fragments. International Journal of Pharmaceutics 420(1), pp. 84-92. (10.1016/j.ijpharm.2011.08.031)
- Izzo, L., Griffiths, P. C., Nilmini, R., King, S. M., Wallom, K., Ferguson, E. L. and Duncan, R. 2011. Impact of polymer tacticity on the physico-chemical behaviour of polymers proposed as therapeutics. International Journal of Pharmaceutics 408(1-2), pp. 213-222. (10.1016/j.ijpharm.2011.02.003)
2010
- Ferguson, E. L., Alshame, A. M. J. and Thomas, D. W. 2010. Evaluation of hyaluronic acid-protein conjugates for polymer masked-unmasked protein therapy. International Journal of Pharmaceutics 402(1-2), pp. 95-102. (10.1016/j.ijpharm.2010.09.029)
- Ferguson, E. L., Richardson, S. C. W. and Duncan, R. 2010. Studies on the mechanism of action of dextrin-phospholipase A2 and its suitability for use in combination therapy. Molecular Pharmaceutics 7(2), pp. 510-521. (10.1021/mp900232a)
- Ferguson, E. L., De Luca, E., Heenan, R. K., King, S. M. and Griffiths, P. C. 2010. Time-Resolved Small-Angle Neutron Scattering as a Tool for Studying Controlled Release from Liposomes using Polymer-Enzyme Conjugates. Macromolecular Rapid Communications 31(19), pp. 1685-1690. (10.1002/marc.201000241)
2009
- Ferguson, E. L. and Duncan, R. 2009. Dextrin-phospholipase A2: Synthesis and evaluation as a bioresponsive anticancer conjugate. Biomacromolecules 10(6), pp. 1358-1364. (10.1021/bm8013022)
- Treetharnmathurot, B., Dieudonné, L., Ferguson, E., Schmaljohann, D., Duncan, R. and Wiwattanapatapee, R. 2009. Dextrin-trypsin and ST-HPMA-trypsin conjugates: Enzyme activity, autolysis and thermal stability. International Journal of Pharmaceutics 373(1-2), pp. 68-76. (10.1016/j.ijpharm.2009.02.008)
2008
- Hardwicke, J., Ferguson, E. L., Moseley, R., Stephens, P., Thomas, D. W. and Duncan, R. 2008. Dextrin-rhEGF conjugates as bioresponsive nanomedicines for wound repair. Journal of Controlled Release 130(3), pp. 275-283. (10.1016/j.jconrel.2008.07.023)
- Richardson, S. C. W. et al. 2008. The use of fluorescence microscopy to define polymer localisation to the late endocytic compartments in cells that are targets for drug delivery. Journal of Controlled Release 127(1), pp. 1-11. (10.1016/j.jconrel.2007.12.015)
- Ferguson, E. L. 2008. Bioresponsive polymer-phospholipase A2 conjugates as novel anti-cancer agents. PhD Thesis, Cardiff University.
Articles
- Rizzo, S., Varache, M., Sayers, E. J., Jones, A. T., Tonks, A., Thomas, D. W. and Ferguson, E. L. 2024. Modification of the antibiotic, colistin, with dextrin causes enhanced cytotoxicity and triggers apoptosis in myeloid leukemia. International Journal of Nanomedicine 19, pp. 5419-5437. (10.2147/IJN.S449185)
- Wootton, H. S., Berry, S. S., Ferguson, E. L., Mahon, C. S. and Miller, G. J. 2024. Adaptable synthesis of chondroitin sulfate disaccharide subtypes preprogrammed for regiospecific O-sulfation. Organic Chemistry (10.26434/chemrxiv-2024-nlm1k)
- Varache, M. et al. 2024. Dextrin conjugation to colistin inhibits its toxicity, cellular uptake and acute kidney injury in vivo. RSC Pharmaceutics 1, pp. 68-79. (10.1039/D3PM00014A)
- Stokniene, J., Varache, M., Rye, P. D., Hill, K. E., Thomas, D. W. and Ferguson, E. L. 2022. Alginate oligosaccharides enhance diffusion and activity of colistin in a mucin-rich environment. Scientific Reports 12, article number: 4986. (10.1038/s41598-022-08927-1)
- Chiron, E., Varache, M., Stokniene, J., Thomas, D. W. and Ferguson, E. L. 2021. A physicochemical assessment of the thermal stability of dextrin–colistin conjugates. Scientific Reports 11, article number: 10600. (10.1038/s41598-021-89946-2)
- Stokniene, J. et al. 2020. Bi-functional alginate oligosaccharide–polymyxin conjugates for improved treatment of multidrug-resistant gram-negative bacterial infections. Pharmaceutics 12(11), article number: 1080. (10.3390/pharmaceutics12111080)
- Varache, M., Powell, L. C., Aarstad, O. A., Williams, T. L., Wenzel, M. N., Thomas, D. W. and Ferguson, E. L. 2019. Polymer masked-unmasked protein therapy: Identification of the active species after amylase-activation of dextrin-colistin conjugates.. Molecular Pharmaceutics 16(7), pp. 3199-3207. (10.1021/acs.molpharmaceut.9b00393)
- Ferguson, E. L. et al. 2018. Controlled release of Dextrin-conjugated growth factors to support growth and differentation of neural stem cells. Stem Cell Research 33, pp. 69-78. (10.1016/j.scr.2018.10.008)
- Powell, L. C. et al. 2018. Targeted disruption of the extracellular polymeric network of pseudomonas aeruginosa biofilms by alginate oligosaccharides. npj Biofilms and Microbiomes 4, article number: 13. (10.1038/s41522-018-0056-3)
- Scomparin, A., Florindo, H. F., Tiram, G., Ferguson, E. L. and Satchi-Fainaro, R. 2017. Two-step polymer- and liposome- enzyme prodrug therapies for cancer: PDEPT and PELT concepts and future perspectives. Advanced Drug Delivery Reviews 118, pp. 52-64. (10.1016/j.addr.2017.09.011)
- Ferguson, E. L., Scomparin, A., Hailu, H. and Satchi-Fainaro, R. 2017. HPMA copolymer-phospholipase C and dextrin-phospholipase A2 as model triggers for polymer enzyme liposome therapy (PELT). Journal of drug targeting 25(9-10), pp. 818-828. (10.1080/1061186X.2017.1358726)
- Pritchard, M. F. et al. 2017. The antimicrobial effects of the alginate oligomer OligoG CF-5/20 are independent of direct bacterial cell membrane disruption. Scientific Reports 7, article number: 44731. (10.1038/srep44731)
- Roberts, J. L., Cattoz, B., Schweins, R., Beck, K., Thomas, D. W., Griffiths, P. C. and Ferguson, E. L. 2016. In vitro evaluation of the interaction of dextrin-colistin conjugates with bacterial lipopolysaccharide. Journal of Medicinal Chemistry 59(2), pp. 647-654. (10.1021/acs.jmedchem.5b01521)
- Azzopardi, E. A., Ferguson, E. L. and Thomas, D. W. 2015. Development and validation of an in vitro pharmacokinetic/pharmacodynamic model to test the antibacterial efficacy of antibiotic polymer conjugates. Antimicrobial Agents and Chemotherapy 59(4), pp. 1837-1843. (10.1128/AAC.03708-14)
- Ferguson, E. L., Azzopardi, E., Roberts, J. L., Walsh, T. R. and Thomas, D. W. 2014. Dextrin-Colistin conjugates as a model bioresponsive treatment for multidrug resistant bacterial infections. Molecular Pharmaceutics 11(12), pp. 4437-4447. (10.1021/mp500584u)
- Azzopardi, E. A., Ferguson, E. L. and Thomas, D. W. 2014. A novel class of bioreponsive nanomedicines for localised reinstatement of bioactivity and specific targeting [Abstract]. The Lancet 383, pp. S9. (10.1016/S0140-6736(14)60272-5)
- Azzopardi, E. A., Ferguson, E. L. and Thomas, D. W. 2013. Colistin past and future: A bibliographic analysis. Journal of Critical Care 28(2), pp. 219.e13-219.e19. (10.1016/j.jcrc.2012.04.008)
- Azzopardi, E. A., Ferguson, E. L. and Thomas, D. W. 2013. The enhanced permeability retention effect: a new paradigm for drug targeting in infection. Journal of Antimicrobial Chemotherapy 68(2), pp. 257-274. (10.1093/jac/dks379)
- Naderi, N., Madani, S. Y., Ferguson, E. L., Mosahebi, A. and Seifalian, A. M. 2013. Carbon nanotubes in the diagnosis and treatment of malignant melanoma. Anti-Cancer Agents in Medicinal Chemistry 13(1), pp. 171-185. (10.2174/1871520611307010171)
- Azzopardi, E. A., Camilleri, L., Moseley, R., Thomas, D. W. and Ferguson, E. L. 2013. Statistical characterization of succinoylated dextrin degradation behavior in human α-amylase. Journal of Carbohydrate Chemistry 32(7), pp. 438-449. (10.1080/07328303.2013.831434)
- Ferguson, E. L., Roberts, J. L., Moseley, R., Griffiths, P. C. and Thomas, D. W. 2011. Evaluation of the physical and biological properties of hyaluronan and hyaluronan fragments. International Journal of Pharmaceutics 420(1), pp. 84-92. (10.1016/j.ijpharm.2011.08.031)
- Izzo, L., Griffiths, P. C., Nilmini, R., King, S. M., Wallom, K., Ferguson, E. L. and Duncan, R. 2011. Impact of polymer tacticity on the physico-chemical behaviour of polymers proposed as therapeutics. International Journal of Pharmaceutics 408(1-2), pp. 213-222. (10.1016/j.ijpharm.2011.02.003)
- Ferguson, E. L., Alshame, A. M. J. and Thomas, D. W. 2010. Evaluation of hyaluronic acid-protein conjugates for polymer masked-unmasked protein therapy. International Journal of Pharmaceutics 402(1-2), pp. 95-102. (10.1016/j.ijpharm.2010.09.029)
- Ferguson, E. L., Richardson, S. C. W. and Duncan, R. 2010. Studies on the mechanism of action of dextrin-phospholipase A2 and its suitability for use in combination therapy. Molecular Pharmaceutics 7(2), pp. 510-521. (10.1021/mp900232a)
- Ferguson, E. L., De Luca, E., Heenan, R. K., King, S. M. and Griffiths, P. C. 2010. Time-Resolved Small-Angle Neutron Scattering as a Tool for Studying Controlled Release from Liposomes using Polymer-Enzyme Conjugates. Macromolecular Rapid Communications 31(19), pp. 1685-1690. (10.1002/marc.201000241)
- Ferguson, E. L. and Duncan, R. 2009. Dextrin-phospholipase A2: Synthesis and evaluation as a bioresponsive anticancer conjugate. Biomacromolecules 10(6), pp. 1358-1364. (10.1021/bm8013022)
- Treetharnmathurot, B., Dieudonné, L., Ferguson, E., Schmaljohann, D., Duncan, R. and Wiwattanapatapee, R. 2009. Dextrin-trypsin and ST-HPMA-trypsin conjugates: Enzyme activity, autolysis and thermal stability. International Journal of Pharmaceutics 373(1-2), pp. 68-76. (10.1016/j.ijpharm.2009.02.008)
- Hardwicke, J., Ferguson, E. L., Moseley, R., Stephens, P., Thomas, D. W. and Duncan, R. 2008. Dextrin-rhEGF conjugates as bioresponsive nanomedicines for wound repair. Journal of Controlled Release 130(3), pp. 275-283. (10.1016/j.jconrel.2008.07.023)
- Richardson, S. C. W. et al. 2008. The use of fluorescence microscopy to define polymer localisation to the late endocytic compartments in cells that are targets for drug delivery. Journal of Controlled Release 127(1), pp. 1-11. (10.1016/j.jconrel.2007.12.015)
Book sections
- Ferguson, E., Varache, M., Stokniene, J. and Thomas, D. 2019. Polysaccharides for protein and peptide conjugation. In: Pasut, G. and Zalipsky, S. eds. Polymer-Protein Conjugates: From Pegylation and Beyond. Elsevier, pp. 421-453., (10.1016/B978-0-444-64081-9.00019-X)
Conferences
- Sharma, P. et al. 2023. In vitro antibiofilm activity of hexylresorcinol lozenges against oropharyngeal pathogens. Presented at: 2023 ERS International Congress, Milan, Italy, 9-13 September 2023. European Respiratory Society, (10.1183/13993003.congress-2023.PA603)
Thesis
- Ferguson, E. L. 2008. Bioresponsive polymer-phospholipase A2 conjugates as novel anti-cancer agents. PhD Thesis, Cardiff University.
- Azzopardi, E. A., Ferguson, E. L. and Thomas, D. W. 2013. The enhanced permeability retention effect: a new paradigm for drug targeting in infection. Journal of Antimicrobial Chemotherapy 68(2), pp. 257-274. (10.1093/jac/dks379)
- Ferguson, E. L., Roberts, J. L., Moseley, R., Griffiths, P. C. and Thomas, D. W. 2011. Evaluation of the physical and biological properties of hyaluronan and hyaluronan fragments. International Journal of Pharmaceutics 420(1), pp. 84-92. (10.1016/j.ijpharm.2011.08.031)
- Ferguson, E. L., Alshame, A. M. J. and Thomas, D. W. 2010. Evaluation of hyaluronic acid-protein conjugates for polymer masked-unmasked protein therapy. International Journal of Pharmaceutics 402(1-2), pp. 95-102. (10.1016/j.ijpharm.2010.09.029)
- Ferguson, E. L., De Luca, E., Heenan, R. K., King, S. M. and Griffiths, P. C. 2010. Time-Resolved Small-Angle Neutron Scattering as a Tool for Studying Controlled Release from Liposomes using Polymer-Enzyme Conjugates. Macromolecular Rapid Communications 31(19), pp. 1685-1690. (10.1002/marc.201000241)
- Ferguson, E. L. and Duncan, R. 2009. Dextrin-phospholipase A2: Synthesis and evaluation as a bioresponsive anticancer conjugate. Biomacromolecules 10(6), pp. 1358-1364. (10.1021/bm8013022)
- Hardwicke, J., Ferguson, E. L., Moseley, R., Stephens, P., Thomas, D. W. and Duncan, R. 2008. Dextrin-rhEGF conjugates as bioresponsive nanomedicines for wound repair. Journal of Controlled Release 130(3), pp. 275-283. (10.1016/j.jconrel.2008.07.023)
Ymchwil
Mae fy ymchwil gyfredol yn canolbwyntio ar ddatblygu polymer sy'n ymateb i ensymau datblygedig sy'n ymateb i amrywiad ffisiolegol a batholegol mewn gweithgaredd ensym i sbarduno rhyddhau llwyth tâl bioactif. Mae fy ymchwil a gyhoeddwyd yn ddiweddar ac a ariannwyd ar hyn o bryd wedi dangos potensial polymer polysacarid i gyflawni rhyddhau cyffuriau safle-benodol (yn seiliedig ar fwy o weithgaredd ensym ar safleoedd llid, e.e. canser a haint). Mae potensial y dulliau therapiwtig hyn i leihau sgîl-effeithiau (ee, neffrotoxicity) a gwella gweithgaredd biolegol y rhiant gyffur hefyd wedi'i ddangos. Nod gwaith parhaus yw optimeiddio dyluniad y polymerau sy'n ymateb i ensymau hyn i wneud y mwyaf o'u potensial clinigol.
Prosiectau cyfredol
Cludwyr cyflenwi cyffuriau newydd sy'n seiliedig ar polysacarid ar gyfer therapiwteg polymer Nod: Archwilio potensial ffynonellau a strwythurau amgen polysacaridau biolegol weithredol fel cludwyr newydd ar gyfer cyffuriau protein a pheptidau.
Datblygu dull nanofeddygaeth ar gyfer targedu canser a heintiau bacteriol ar yr un prydNod: Archwilio gweithgaredd gwrth-ganser conjugates dextrin-colistin.
Dylunio a chynulliad oligosaccharidau wedi'u teilwra fel therapiwteg polymer ar gyfer triniaeth well o heintiau anadlol cronig Nod: Cynhyrchu a nodweddu llyfrgell gyfun algin oligosaccharide ("OligoG")-polymyxin i optimeiddio swyddogaethau gwrthficrobaidd y cyffuriau dewis olaf hyn.
Mae Dextrin-colistin yn cyd-fynd fel triniaeth bioymatebol enghreifftiol ar gyfer heintiau bacteriol sy'n gwrthsefyll aml-gyffur
Anelu: Datblygu system gyflenwi newydd sy'n seiliedig ar nanofeddyginiaeth i dargedu darparu colistin i safleoedd llid; cynyddu bio-weithgarwch / bioargaeledd, lleihau gwenwyndra systemig a gwella effeithiolrwydd clinigol.
Datblygu modelau in vitro i astudio patrymau rhyddhau cyffuriau o systemau cyflenwi cyffuriau bioymatebol
Anelu: Nodweddu patrymau rhyddhau cyffuriau ac effeithiau fferyllolegol amser real polymer bioymatebol yn cyd-fynd mewn amgylcheddau ffisiolegol efelychiadol.
Cyllid
- 2024: Cyllid Diwylliant Ymchwil Prifysgol Caerdydd: 'Digwyddiad Uned Asesu 3 Dangos a Dweud' (£2931, ymgeisydd arweiniol).
- 2023-2024: Gwobr Cyflymu Effaith MRC: 'Ail-bwrpasu dextrin-colistin yn cyd-drefnu i atal llid aberrant mewn osteoarthritis' (£43,437, cyd-brif ymchwilydd).
- 2023-2024: Gwobr Offer Craidd EPSRC (EP/X034739/1): Galwad Offer EPSRC 2022: Prifysgol Caerdydd (£457,080, cyd-ymchwilydd).
- 2022-2024: EPSRC New Horizons (EP/X019136/1): 'Biopolymerau bioymatebol y genhedlaeth nesaf peirianneg: proteoglycans cartilag memetig' (£196,228, cyd-ymchwilydd).
- 2022-2025: Llywodraeth Saudi Arabia (ysgoloriaeth PhD): (£125,850, prif ymchwilydd).
- 2022: Wellcome Trust (Cyfrif Prosiect Cyfieithu Sefydliadol): 'Datblygu dull nanofeddygaeth i leihau sgîl-effeithiau annerbyniol bexarotene' (£24,831, cyd-ymchwilydd).
- 2020-2022: Cyngor Ymchwil Meddygol (Hyder mewn Cysyniad): 'Potensial polysacaridau lactobacillus spp.-deillio fel cludwyr bi-swyddogaethol newydd mewn cyfuniadau polymerau' (£ 53,468, prif ymchwilydd).
- 2020-2021: Wellcome Trust (Cronfa Cymorth Strategol Sefydliadol Ailgysylltu â Gwyddoniaeth): 'Datblygu nanoparticle-antibiotig bio-ysgogedig bio-ysgogi i dargedu canser: effaith addasu ar cytotoxicity a llwybrau cysylltiedig epigenetig' (£76,855, noddwr ymchwil).
- 2019: Offer Sefydliadol EPSRC ECR: 'Goniometer ongl gyswllt a microbalans grisial cwarts' (£48,000, cyd-ymchwilydd).
- 2018-2022: Cyngor Ymchwil Norwyaidd (281920): 'Cynhyrchion oligomer alginate newydd ar gyfer gwell darpariaeth fferyllol ar draws rhwystr mwcosal (Mucos-ALG) ' (£297,397, cyd-ymchwilydd).
- 2018-2019: Grant Ymchwil y Gymdeithas Frenhinol (RG \ R2\180069): 'Datblygu dull ar gyfer dadansoddiad ffisicocemegol o saccharidau o gyfuniadau ploysaccharide-peptid' (£17,986.80, prif ymchwilydd).
- 2018-2019: Gwobr Kickstart Drosiadol Ymddiriedolaeth Wellcome ISSF3: Datblygu dull nanofeddygaeth ar gyfer targedu canser a heintiau bacteriol ar yr un pryd (£ 49,645, prif ymchwilydd).
- 2016-2021: Grant Ymchwil Ymchwilydd Newydd MRC (MR/N023633/1): 'Cronni a nephrotoxicity o gyfuniadau dextrin-colistin' (£406,496, prif ymchwilydd).
- 2013-2013: Grant Grŵp Datblygu Ymchwil Microbioleg a Heintiau (MITReG): "Dulliau nanogwrthfiotig o gyflenwi gwrthfiotigau" (£4,000, prif ymchwilydd).
- 2012: Grant EPSRC (EP/K031635/1): 'Eitemau bach o offer ymchwil ym Mhrifysgol Caerdydd' (£498,293, cyd-ymchwilydd).
- 2012: Astudiaeth SANS yng nghyfleuster ILL: 'Ymchwilio i gydffurfiad datrysiad a mecanwaith gweithredu oligosaccharidau algin gwrthficrobaidd (OligoG)' (£19,699, prif ymchwilydd).
- 2011: Astudiaeth SANS yng nghyfleuster ILL: 'Cyfuniadau polymer-gwrthficrobaidd newydd; Eu cydffurfiad datrysiad, ymddygiad hunan-gysylltiad a rhyngweithio â lipopolysacaridau '(£19,172, cyd-ymchwilydd).
- 2010-2011: Gwobr Gwerth mewn Pobl Ymddiriedolaeth Wellcome (£41,000 wedi'i ddyfarnu, prif ymchwilydd).
- 2009-2010: Cynllun Ariannu Llwybr Datblygiadol MRC: 'Mae peptid polymer-peptid bioymatebol yn cyd-fynd fel asiantau gwrthfacterol newydd' (£27,000 wedi'i ddyfarnu, prif ymchwilydd).
- 2008: Astudiaeth SANS yng nghyfleuster ISIS: 'Ymchwilio i Dextrin-Phospholipase A2 Cydgyfarfod fel Sbardun ar gyfer Therapi Liposome Ensym Polymer (PELT)' (£22,120 wedi'i ddyfarnu, prif ymchwilydd).
- 2008: Astudiaeth SANS yng nghyfleuster ISIS: 'Nodweddu Strwythurol Cyfres o Polymer-Protein yn Cyd-drefnu ar gyfer Triniaethau Clwyfau Cronig' (£10,870, cyd-ymchwilydd).
Patentau
- Ferguson E, Thomas DW, Dessen A, Rye P (2016) Bacitracin-alginate oligomer yn cydymffurfio. GB201617862. D0.
- Ferguson E, Thomas DW, Dessen A, Rye P (2017) Polymyxin-alginate oligomer yn cydymffurfio. GB201617860D0, GB201714710D0.
- Ferguson EL, Thomas DW, Walsh T (2012) Cyfuniadau therapiwtig. GB201010500D0, EP2585114B1, ES2523507T3, US8835380B2.
ID ORCID: orcid.org/0000-0002-0125-0234
Addysgu
|
Blwyddyn o/i |
Teitl y modiwl/cwrs |
Lefel astudio (e.e. blwyddyn 1) |
Rôl |
|
2023 - presennol |
Addysg ryngbroffesiynol |
Blynyddoedd 1-5 |
Arweinydd pwnc |
|
2018 - 2024 |
MSc mewn Peirianneg Meinwe |
Meistr (wedi'i ddysgu) |
Dirprwy gyfarwyddwr rhaglen |
|
2017 - presennol |
Addysg ryngbroffesiynol |
Blynyddoedd 1 a 2 |
Arweinydd y cwrs a'r hwylusydd |
|
2017 - presennol
|
DET068 (atgyweirio meinwe, adfywio a dulliau gwyddonol) |
Meistr (wedi'i ddysgu)
|
Darlithydd ac arholwr
|
|
2013 - 2023
|
DET002 (Peirianneg meinwe: o'r cysyniad i ymarfer clinigol) |
Meistr (wedi'i ddysgu)
|
Arweinydd y modiwl |
|
2013 - presennol
|
Prosiectau ymchwil blwyddyn olaf, Deintyddfa (BDS) |
Blwyddyn 45 |
Goruchwyliwr prosiect
|
|
2012 - presennol |
Cyflwyniadau PowerPoint, BDS |
Blwyddyn 3 |
Arholwr
|
|
2012 - presennol |
Prosiect poster, BDS |
Blwyddyn 2 |
Arholwr |
|
2012 – presennol |
Proffesiynoldeb viva, BDS |
Blwyddyn 1
|
Arholwr
|
|
2012 – presennol |
Traethawd estynedig, BDS |
Blwyddyn 2 |
Arholwr |
|
2009 – presennol
|
DET028 (Bioleg Cellog a Moleciwlaidd) MSc mewn Mewnblaneg |
Meistr (wedi'i ddysgu)
|
Darlithydd ac arholwr
|
|
2009 - presennol |
DET002 (Peirianneg meinwe: o'r cysyniad i ymarfer clinigol) |
Meistr (wedi'i ddysgu) |
Darlithydd ac arholwr |
Cymwysterau
- 2019: Uwch Gymrawd yr Academi Addysg Uwch
- 2014: Cymrodyr, Academi Addysg Uwch
Bywgraffiad
Graddiais o Brifysgol Manceinion gyda gradd Meistr Fferylliaeth dosbarth Cyntaf, ar ôl ennill gwybodaeth eang o egwyddorion a thechnegau gwyddorau fferyllol. Arweiniodd hyn i mi weithio yn y sector fferyllol diwydiant (AstraZeneca) lle cefais brofiad ymarferol o'r sgiliau hyn. Ar ôl cymhwyso fel fferyllydd cofrestredig, penderfynais ddilyn fy niddordeb cynyddol mewn datblygu systemau cyflenwi cyffuriau newydd gan fod fy mhrofiadau fferylliaeth glinigol wedi amlygu'r angen clinigol am driniaethau newydd. Cwblheais PhD gyda'r Athro Ruth Duncan ym Mhrifysgol Caerdydd yn 2008, lle datblygais gyfuniad polymer-ffosffolipase bioymatebol ar gyfer trin canser y fron. Roedd yr ymchwil hon yn 'cadarnhau' fy niddordeb hirsefydlog mewn defnyddio polymerau bioddiraddadwy naturiol fel cludwyr newydd ar gyfer asiantau bioactif.
Ar ôl dangos dichonoldeb therapiwteg polymer bioymatebol mewn canser, canolbwyntiodd fy niddordebau ar archwilio cymwysiadau clinigol newydd. Ar ôl nodi meddygaeth adfywiol fel maes lle gallai cyfuniadau polymer bioymatebol fod â photensial mawr, ymunais â chonsortiwm dan arweiniad Llwyfan Nanofeddygaeth EPSRC rhyngddisgyblaethol. Gan ddefnyddio technegau dadansoddol soffistigedig iawn i ddatblygu a phrofi cyfuniadau ffactor twf deextrin, fe wnaethom ddatblygu'r therapiwteg polymer cyntaf ar gyfer atgyweirio meinweoedd.
Yn fwy diweddar, galluogodd fy nghyllid gan MRC ac Ymddiriedolaeth Wellcome fy ngrŵp i ddylunio a darparu'r 'nanogwrthfiotig' bioymatebol cyntaf yn seiliedig ar gyfuniadau deextrin-colistin, sy'n dangos gwell sefydlogrwydd cyffuriau, ffarmacocineteg a chadw gweithgaredd gwrthficrobaidd. Mae'r cyllid hwn wedi cefnogi datblygiad consortiwm bach, dan arweiniad fi, clinigwyr, ôl-raddedigion a chynorthwyydd ymchwil, ac wedi denu cyllid pellach, gan gynnwys Grant Ymchwil Ymchwilydd Newydd MRC ac Ymddiriedolaeth Wellcome i archwilio targedu canser a heintiau bacteriol ar yr un pryd gyda'n nanogwrthfiotig. Fy ymchwil cyfredol yw datblygu therapiwteg polymer sy'n ymateb i ensymau datblygedig ar gyfer ystod o dargedau newydd a chymwysiadau clinigol newydd.
Cefais fy mhenodi'n Ddarlithydd Therapiwteg Polymer ym mis Ionawr 2013, a'm dyrchafu'n Uwch-ddarlithydd ym mis Awst 2017. Fe wnes i gais llwyddiannus am ddyrchafiad i Ddarllenydd ym mis Awst 2020. Cefais fy mhenodi'n Gyfarwyddwr Ymchwil ar gyfer yr Ysgol Deintyddiaeth ym mis Awst 2021.
Cyfleoedd PhD ar un o'r pynciau canlynol:
a. Therapiwteg polymer sy'n ymateb i ensym uwch ar gyfer meddygaeth adfywiol, canser a therapïau gwrth-heintus
b. Datblygu a nodweddu nanogwrthfiotigau (gan gynnwys diogelwch ac effaith ar ddatblygu ymwrthedd gwrthficrobaidd)
c. Camfanteisio ar ficro-amgylchedd meinwe (canser, haint, llid) mewn therapi
Anrhydeddau a dyfarniadau
- Jun 2016: Poster prize. Cardiff and Vale UHB International Clinical Trials Conference. Cardiff, UK (3rd prize awarded).
- Jun 2015: Poster prize. Cardiff and Vale UHB Research and Development Conference. Cardiff, UK (3rd prize awarded).
- May 2014: Oral presentation. 10th International Symposium on Polymer Therapeutics: From Laboratory to Clinical Practice. Valencia, Spain (2nd prize awarded).
- Dec 2012: Competitive travel grant. Microbiology and Infection Translational Research Group (MITReG) (£400).
- May 2011: Science team award for ‘Best Interdisciplinary Dynamics’, SARTRE Science Showcase. Newport, UK.
- Nov 2010: Oral presentation. Association of British Academic Oral and Maxillofacial Surgeons Annual Meeting. Cardiff, UK (1st prize awarded).
- 2007: Competitive travel grants. Merck Sharp & Dohme (£500), Controlled Release Society ($125).
- Jun ’06: Oral presentation. Highlights of student posters, 33rd Annual Meeting and Exposition of the Controlled Release Society. Vienna, Austria (1st prize awarded).
- 2006: Competitive travel grants. Graduate School of Biomedical and Life Sciences travel grant (£300), Thomas Morgan travel grant (£200).
- Apr 2004: Poster prize. Postgraduate research day, Welsh School of Pharmacy. Cardiff, UK (1st prize awarded).
- 8 prizes awarded to PhD students under my supervision.
Aelodaethau proffesiynol
Royal Pharmaceutical Society (RPS)General Pharmaceutical Council (GPhC)
Cardiff Institute for Tissue Engineering & Repair (CITER)
Microbiology and Infection Translational Research Group (MITReG)European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
British Society of Antimicrobial Chemotherapy (BSAC)
Safleoedd academaidd blaenorol
- Jan 2012 - Jul 2017: Lecturer in Polymer Therapeutics, School of Dentistry, Cardiff, UK.
- Nov 2008 - Dec 2012: Research Associate in Polymer Therapeutics, School of Dentistry, Cardiff, UK.
- May 2008 - Oct 2008: Postdoctoral Research Scientist (Nanomedicines EPSRC Platform Grant), Schools of Chemistry and Pharmacy, Cardiff, UK.
Pwyllgorau ac adolygu
INSTITUTIONAL RESPONSIBILITIES
- 2021 - present: Director of Research (Dentistry), Cardiff University, UK
- 2018 - present: Impact Lead (UoA3), Cardiff University, UK
- 2018 - present: Senior Management Committee (Dentistry), Cardiff University, UK
- 2016 - present: Wellcome Trust ISSF3 grant panel member, Cardiff University, UK
- 2016 - present: Research Committee (Dentistry), Cardiff University, UK
- 2015 - 2016: Enterprise, Engagement and Impact Committee (Dentistry), Cardiff University, UK
- 2014 - present: Postgraduate Research Admissions and Monitoring Committee (Dentistry), Cardiff University, UK
- 2014 - present: Impact and Innovation Committee (College of Biological and Life Sciences), Cardiff University, UK
- 2014 -present: Impact Lead (Dentistry), Cardiff University, UK
- 2013 - 2017: Research Ethics Committee (Dentistry), Cardiff University, UK
- 2012 - 2018: People, Equality and Diversity Committee (Dentistry), Cardiff University, UK
COMMISSIONS OF TRUST
- 2019 - present: Associate Editor, Nano-Based Drug Delivery - Frontiers in Medical Technology
- 2019 - present: Editorial board member, Scientific Reports
- 2019: External examiner, Monash University
- 2018: External examiner, University of Strathclyde
- 2016 - present: Chair of PhD examination panel (x2), Cardiff University, UK
- 2011 - present: Grant reviewing: BBSRC, EPSRC, MRC, UKRI, Wellcome Trust and British Society for Antimicrobial Chemotherapy
- 2010 - present: Reviewer for over 20 journals, e.g.: Nature, Biomacromolecules, Nanomedicine: Nanotechnology, Biology, and Medicine, PLoS ONE, International Journal of Nanomedicine, Journal of the American Chemical Society, Macromolecular Bioscience
Meysydd goruchwyliaeth
I am interested in supervising PhD students in the areas of:
- Polymer therapeutics
- Drug delivery
- Nanomedicine
- Antimicrobial resistance
Goruchwyliaeth gyfredol
Ghaida Khalid K Almuthri Almuthri
Myfyriwr ymchwil
Prosiectau'r gorffennol
- Stokniene, Joana 2019 Dylunio a chynulliad oligosaccharidau wedi'u teilwra fel therapiwteg polymer ar gyfer triniaeth well o glefyd anadlol cronig. goruchwyliwr arweiniol
- Azzopardi, Ernest Anthony 2013 Mae dextrin-colistin bioymatebol yn cyd-fynd fel asiantau gwrthficrobaidd ar gyfer trin haint Gram-negyddol. Cyd-oruchwyliwr
Themâu ymchwil
Arbenigeddau
- Nanofeddygaeth
- Cyflwyno cyffuriau
- Therapiwteg polymer
- Nodweddiad ffysicocemegol
- Cemeg ddadansoddol